glp-1/gip receptor agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight GIP and GLP‐1, the two
Description
Discussion In our study, four principal findings emerged: (1) People receiving GLP-1 RA were older, more frequently female, and had a higher burden of endocrine, metabolic and gastrointestinal disorders compared to non GLP-1 RA Users
Cline Gounder has more
The kidney and cardiovascular outcome trials
Semaglutide Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management
Eli Lilly, which has been directing patients to various telehealth sites as it sells its blockbuster obesity medication Zepbound, is broadening its reach, announcing a partnership Wednesday with major telehealth platform Ro
Metformin is especially beneficial for patients with glp-1 therapy or those who struggle with weight management alongside metabolic challenges
